SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-042284
Filing Date
2024-05-13
Accepted
2024-05-13 16:02:37
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205749-10q_virpax.htm   iXBRL 10-Q 515649
2 CERTIFICATION ea020574901ex31-1_virpax.htm EX-31.1 9548
3 CERTIFICATION ea020574901ex31-2_virpax.htm EX-31.2 9557
4 CERTIFICATION ea020574901ex32-1_virpax.htm EX-32.1 3772
5 CERTIFICATION ea020574901ex32-2_virpax.htm EX-32.2 3738
  Complete submission text file 0001213900-24-042284.txt   3255494

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE vrpx-20240331.xsd EX-101.SCH 34428
7 XBRL CALCULATION FILE vrpx-20240331_cal.xml EX-101.CAL 19838
8 XBRL DEFINITION FILE vrpx-20240331_def.xml EX-101.DEF 160947
9 XBRL LABEL FILE vrpx-20240331_lab.xml EX-101.LAB 278388
10 XBRL PRESENTATION FILE vrpx-20240331_pre.xml EX-101.PRE 152580
58 EXTRACTED XBRL INSTANCE DOCUMENT ea0205749-10q_virpax_htm.xml XML 255467
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40064 | Film No.: 24938900
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)